NR1H4 and metabolic dysfunction-associated steatohepatitis: Among those, obeticholic acid (OCA), a semi-synthetic BA analogue based on CDCA structure which has already been approved to treat primary biliary cholangitis in humans, showed all the beneficial health effects of FXR activation when administered in animals [66,169,170,171] and is currently a good candidate for the treatment of NASH and T2DM [16].